

What is claimed is:

1. An agent for preventing and/or treating hematologic malignancies, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 in the sequence listing.
2. An agent for preventing and/or treating hematologic malignancies, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 8 and 10 in the sequence listing.
3. The agent for preventing and/or treating hematologic malignancies according to Claim 2, further comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 6, 7 and 9 in the sequence listing.
4. An agent for preventing and/or treating hematologic malignancies, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2 and 4 in the sequence listing.
5. An agent for preventing and/or treating hematologic malignancies, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 and 10 in the sequence listing.
6. An agent for preventing and/or treating hematologic malignancies, comprising as an active ingredient at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 and 8 in the sequence listing.
7. The agent for preventing and/or treating hematologic malignancies according to any one of Claims 1 to 6, further comprising an adjuvant.
8. The preventing and/or treating agent according to any one of Claims 1 to 7, wherein the hematologic malignancies are hematologic malignancies having HLA-A24 molecules on their cell surface.
9. The preventing and/or treating agent according to any one of Claims 1 to 7, wherein the hematologic malignancies are hematologic malignancies which have HLA-A24



molecules on their cell surface and express a protein containing the peptide that is an active ingredient for the preventing and/or treating agent.

10. The agent for preventing and/or treating hematologic malignancies according to any one of Claims 1 to 9, wherein the agent is used as a cancer vaccine for the hematologic malignancies.

11. A medicament for preventing and/or treating hematologic malignancies having HLA-A24 molecules on their cell surface, comprising at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 8 and 10 in the sequence listing and an adjuvant.

12. A method for preventing and/or treating hematologic malignancies that have HLA-A24 molecules on their cell surface, comprising administering a therapeutically effective amount of at least one peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 5, 8 and 10 in the sequence listing together with an adjuvant.